Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Invested Capital (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Invested Capital for 3 consecutive years, with $108.6 million as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 18.74% to $108.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $108.6 million through Dec 2025, down 18.74% year-over-year, with the annual reading at $108.6 million for FY2025, 18.74% down from the prior year.
  • Invested Capital for Q4 2025 was $108.6 million at Inhibrx Biosciences, down from $136.7 million in the prior quarter.
  • The five-year high for Invested Capital was $219.4 million in Q2 2024, with the low at -$24.8 million in Q2 2023.
  • Average Invested Capital over 3 years is $118.0 million, with a median of $133.6 million recorded in 2024.
  • Peak annual rise in Invested Capital hit 1569.23% in 2025, while the deepest fall reached 23.49% in 2025.
  • Over 3 years, Invested Capital stood at $43.5 million in 2023, then soared by 207.07% to $133.6 million in 2024, then fell by 18.74% to $108.6 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $108.6 million, $136.7 million, and $167.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.